Table 2 Analyses of OS in subgroups of patients with different clinical features

Aged < 65 years

Total

5

0.84

0.74–0.94

0.003

42%

0.14

1st Line

3

0.79

0.68–0.91

0.001

0%

0.89

 ≥ 2nd Line

2

0.96

0.61–1.51

0.87

78%

0.03

monotherapy

3

0.91

0.70–1.18

0.48

63%

0.07

combination therapy

2

0.77

0.65–0.92

0.004

0%

0.81

Aged ≥ 65 years

Total

5

0.97

0.84–1.11

0.62

0%

0.99

1st Line

3

0.98

0.83–1.16

0.83

0%

0.97

 ≥ 2nd Line

2

0.92

0.71–1.20

0.54

0%

0.85

monotherapy

3

0.94

0.78–1.15

0.56

0%

0.95

combination therapy

2

0.99

0.81–1.20

0.90

0%

0.83

Female

Total

5

0.98

0.83–1.16

0.82

24%

0.26

1st Line

3

0.93

0.76–1.14

0.46

0%

0.91

 ≥ 2nd Line

2

1.12

0.60–2.09

0.73

75%

0.04

monotherapy

3

1.03

0.71–1.49

0.88

60%

0.08

combination therapy

2

0.94

0.73–1.21

0.64

0%

0.70

Male

Total

5

0.88

0.79–0.98

0.02

0%

0.93

1st Line

3

0.86

0.76–0.98

0.02

0%

0.95

 ≥ 2nd Line

2

0.93

0.76–1.13

0.45

0%

0.52

monotherapy

3

0.91

0.78–1.05

0.20

0%

0.77

combination therapy

2

0.85

0.73–1.00

0.04

0%

0.84

PS 0

Total

5

0.93

0.77–1.14

0.51

51%

0.09

1st Line

3

0.93

0.79–1.09

0.35

0%

0.77

 ≥ 2nd Line

2

1.00

0.47–2.12

1.00

87%

0.006

monotherapy

3

0.94

0.63–1.40

0.77

74%

0.02

combination therapy

2

0.95

0.79–1.15

0.62

0%

0.62

PS 1

Total

5

0.89

0.79–1.01

0.06

0%

0.60

1st Line

3

0.84

0.73–0.98

0.02

0%

0.61

 ≥ 2nd Line

2

1.00

0.81–1.23

0.98

0%

0.88

monotherapy

3

0.97

0.83–1.15

0.75

0%

0.93

combination therapy

2

0.80

0.67–0.96

0.01

0%

0.86

Intestinal type

Total

4

0.88

0.74–1.03

0.12

0%

0.71

1st Line

3

0.90

0.76–1.08

0.26

0%

0.94

 ≥ 2nd Line

1

0.66

0.40–1.11

0.12

monotherapy

2

0.84

0.64–1.10

0.20

9%

0.29

combination therapy

2

0.90

0.73–1.11

0.32

0%

0.73

Diffuse type

Total

4

0.78

0.62–1.00

0.05

54%

0.09

1st Line

3

0.76

0.56–1.03

0.08

69%

0.04

 ≥ 2nd Line

1

0.88

0.54–1.45

0.63

monotherapy

2

0.77

0.59–1.00

0.05

0%

0.51

combination therapy

2

0.77

0.47–1.28

0.32

83%

0.01

Previous gastrectomy

Total

3

0.88

0.71–1.11

0.28

0%

0.78

1st Line

3

0.88

0.71–1.11

0.28

0%

0.78

monotherapy

1

0.79

0.52–1.21

0.28

combination therapy

2

0.92

0.71–1.20

0.56

0%

0.71

No previous gastrectomy

Total

3

0.89

0.79–1.01

0.07

0%

0.65

1st Line

3

0.89

0.79–1.01

0.07

0%

0.65

monotherapy

1

0.94

0.76–1.17

0.59

combination therapy

2

0.87

0.75–1.01

0.06

0%

0.50

Primary gastric tumor

Total

5

0.90

0.81–1.01

0.07

35%

0.19

1st Line

3

0.84

0.74–0.96

0.009

0%

0.90

 ≥ 2nd Line

2

1.07

0.88–1.30

0.50

47%

0.17

monotherapy

3

0.97

0.78–1.22

0.82

57%

0.10

combination therapy

2

0.84

0.72–0.99

0.04

0%

0.67

Primary oesophagogastric junction tumor

Total

5

0.88

0.74–1.06

0.17

19%

0.30

1st Line

3

1.01

0.80–1.27

0.95

0%

0.92

 ≥ 2nd Line

2

0.71

0.53–0.95

0.02

28%

0.24

monotherapy

3

0.83

0.59–1.16

0.27

54%

0.11

combination therapy

2

0.97

0.71–1.31

0.84

0%

0.90

TC < 1%

Total

2

1.01

0.73–1.40

0.94

71%

0.06

1st Line

1

0.87

0.72–1.06

0.17

 ≥ 2nd Line

1

1.22

0.91–1.64

0.18

monotherapy

1

1.22

0.91–1.64

0.18

combination therapy

1

0.87

0.72–1.06

0.17

TC ≥ 1%

Total

2

1.00

0.72–1.41

0.98

0%

0.73

1st Line

1

1.06

0.67–1.68

0.80

 ≥ 2nd Line

1

0.94

0.57–1.55

0.81

monotherapy

1

0.94

0.57–1.55

0.81

combination therapy

1

1.06

0.67–1.68

0.80

CPS ≥ 1

Total

3

0.85

0.75–0.97

0.02

0%

0.86

1st Line

2

0.87

0.74–1.02

0.08

0%

0.70

 ≥ 2nd Line

1

0.82

0.66–1.03

0.09

monotherapy

2

0.86

0.72–1.02

0.08

0%

0.59

combination therapy

1

0.85

0.70–1.03

0.10

CPS ≥ 10

Total

3

0.74

0.60–0.92

0.005

0%

0.53

1st Line

2

0.77

0.61–0.97

0.03

0%

0.37

 ≥ 2nd Line

1

0.64

0.41–1.02

0.06

monotherapy

2

0.67

0.51–0.89

0.005

0%

0.81

combination therapy

1

0.85

0.62–1.17

0.32

1st line therapy

Total

3

0.88

0.78–0.99

0.04

0%

0.89

monotherapy

1

0.91

0.69–1.18

0.47

combination therapy

2

0.88

0.77–1.00

0.05

0%

0.67

 ≥ 2nd line therapy

Total

2

0.96

0.71–1.30

0.80

73%

0.05

monotherapy

2

0.96

0.71–1.30

0.80